NCT07342478
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 6 → 9 locations
- Minor Study sites: 8 to 9
- Minor Study sites: 7 to 8
- Notable Eligibility criteria expanded, about 17 words
- Study sites: 6 to 7
- Secondary endpoints: details revised at 3 of 7 entries
- Minor Study sites: 5 to 6v6
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 4 to 5v5
- Minor Study sites: 3 to 4v4
- Notable Recruitment opened
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Jan 30, 2026 to Apr 23, 2026
- Notable Eligibility criteria shortened, about 29 words
- Secondary endpoints: details revised at 7 of 7 entries
- Study title expanded, about 3 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
PFS assessed by IRC
Timeframe: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
Secondary (7)
OS
PFS assessed by INV
ORR
DOR
TTNT
Show 2 moreShow less
EFS
Safety and tolerability
Arms and interventions
RocbrutinibExperimental
200mg daily
PirtobrutinibActive comparator
200mg daily
Drugs: Rocbrutinib, Pirtobrutinib
Sites
10 sites in 2 countries
United States 7, France 3